InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.58
(
-0.14%
)
Bitcoin
65,111.96
(
0.22%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ariadndndough

Send PM Follow Ignore
Followers 29
Posts 4738
Boards Moderated 0
Alias Born 12/27/2007

ariadndndough

Re: None

Wednesday, 01/04/2012 8:48:08 AM

Wednesday, January 04, 2012 8:48:08 AM

Post# of 252255
Ariad target raised to $23 from $18 at BMO Capital
After Ariad raised about $243M from a public offering, BMO Capital believes that the company is poised to launch its CML treatment, ponatinib, globally by the end of 2012 or early 2013. After speaking with an expert physician, the firm thinks that the unmet need in CML may be underestimated, and it maintains an Outperform rating on Ariad. :theflyonthewall.com


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up